Social anxiety disorder is characterized by marked fear of performance, excessive fear of scrutiny, and fear of acting in a way that will be embarrassing. Although the incidence of social anxiety disorder is approximately 13%, this disorder has been termed “the neglected anxiety disorder” because it is often missed as a diagnosis. Social anxiety disorder has an early onset in most patients and tends to manifest during adolescence. However, many patients do not receive therapy until a comorbid disorder (e.g., panic) is diagnosed later in life. There are 2 distinct subtypes of social anxiety disorder, generalized and nongeneralized, that differ in terms of symptoms, course of illness, morbidity, pathophysiology, and response to treatment. Both pharmacologic and psychotherapeutic treatments are effective, and the 2 modalities have complementary strengths. The selective serotonin reuptake inhibitors may be considered first-line therapy for the generalized subtype of social anxiety disorder because of proved efficacy and well-tolerated adverse effect profiles. Other agents may be useful for treatment-refractory patients. However, there is a substantial rate of relapse even after prolonged treatment. There is evidence that patients who receive cognitive-behavioral therapy may have lower rates of relapse. Early and aggressive treatment of social anxiety disorder may prevent development of comorbid disorders and can substantially improve patients’ quality of life.

From the Anxiety Disorders Clinic, New York State Psychiatric Institute, New York.

Presented at the symposium “New Treatments for Anxiety Disorders: Clinical Approaches for Successful Outcomes,” which was held May 31, 1998, in Toronto, Ontario, Canada. This symposium was held in conjunction with the 151st annual meeting of the American Psychiatric Association and supported by an unrestricted educational grant from SmithKline Beecham Pharmaceuticals.

Reprint requests to: Michael R. Liebowitz, M.D., New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032 (e-mail: liebowitz@nyspi.cpmc.columbia.edu).

Another disturbing feature of social anxiety disorder is the early onset of the disease. The mean age at onset for social anxiety disorder is 15.5 years, and onset after the age of 25 years is uncommon. Patients often recall initial symptoms of shyness and behavioral inhibition in the first 2 decades of life. If left untreated, social anxiety disorder is often a chronic disease and usually does not resolve spontaneously.

Many patients with social anxiety disorder develop substantial functional disability. More than half of patients with social anxiety disorder suffer impairment in meeting educational goals, maintaining employment, and developing relationships. Not surprisingly, social anxiety disorder is associated with financial difficulties. Twenty percent of patients with social anxiety disorder are on welfare. There is evidence that 50% of patients with social anxiety disorder have tried alcohol to relieve anxiety. Patients with social anxiety disorder also are more likely to live with their parents and may be unable to date or maintain romantic relationships.

**DIAGNOSIS**

Patients with social anxiety disorder tend not to seek psychiatric care and initially may present to general practitioners with nondescript symptoms. Because these individuals are fearful of social interactions, patients may not feel comfortable discussing symptoms with a physician.
Patients with social anxiety disorder often describe panic attacks that may cause clinicians to suspect panic disorder. In these cases, it is critical to determine the circumstances of the panic attacks. For example, a person with social anxiety disorder may feel panicked on a subway car only if other people are looking at him, but would be perfectly comfortable alone in the same subway car. Conversely, patients with panic disorder may experience attacks at any time and may actually feel more comfortable in the presence of other people who might help them in the event of an attack.

 Chronic depression often is a consequence of social phobia, and many patients with social anxiety disorder present with depressive symptoms. However, a careful history usually reveals that the patient had symptoms of social anxiety disorder before depression. Avoidant personality disorder has many features that overlap with social anxiety disorder. Schizoid conditions are distinguished from social anxiety disorder because patients with these symptoms have no desire to relate to other individuals, whereas patients with social anxiety disorder feel isolated and would seek personal relationships if they were not so anxious. Patients with social anxiety secondary to minor physical abnormalities, such as a stutter or familial tremor, are excluded from the diagnosis of social anxiety disorder because of the medical cause for their condition. However, these patients tend to have anxiety symptoms and treatment responses similar to those experienced by patients with social anxiety disorder. Patients with offensive-type social phobia erroneously believe that their presence or body odor makes others uncomfortable, leading to social avoidance. This type of social anxiety disorder is noted most frequently in Asian countries and also responds well to treatment.

**Comorbidity**

Because social anxiety disorder has an early onset, it precedes other comorbid conditions in more than 70% of patients. Common comorbidities include agoraphobia, simple phobia, major depression, substance abuse disorders, and obsessive-compulsive disorder. In a survey of 123 patients with social anxiety disorder, the rates of comorbid simple phobia (63%), agoraphobia (47%), generalized anxiety disorder (20%), depression (14%), alcohol abuse (12%), and panic disorder (10%) were exceptionally high, and 10% of patients had attempted suicide. Many
patients with social anxiety disorder attempt to alleviate their symptoms by drinking alcohol, and high rates of alcohol abuse and dependence may result.\textsuperscript{4,6,7} Data from the Epidemiologic Catchment Area study indicate that patients with social anxiety disorder are more likely to have suicidal thoughts compared with control patients, and the incidence of attempted suicide is higher in patients with comorbid conditions.\textsuperscript{5} It is clear that patients with social anxiety disorder are at increased risk for developing comorbid disorders. However, early diagnosis and treatment of social anxiety disorder may prevent other disorders from developing.

**PATHOPHYSIOLOGY**

Nongeneralized social anxiety disorder may be associated with peripheral autonomic involvement. For example, anxiety symptoms and heart rate increase measurably when a person with nongeneralized social anxiety disorder is asked to speak in public.\textsuperscript{12} Treatment with β-blockers on an as-needed basis significantly decreases the autonomic response and alleviates anxiety in these patients. However, generalized social anxiety disorder is a different condition and may be associated with a much different pathophysiology. Although many patients with generalized social anxiety disorder have public-speaking anxiety, they do not experience the same degree of autonomic arousal when asked to speak in public as patients with nongeneralized social anxiety disorder and do not seem to be as effectively treated with β-blockers.

It is hypothesized that patients with generalized social anxiety disorder may have central serotonergic dysregulation. Knutson and colleagues\textsuperscript{13} demonstrated that normal subjects treated with paroxetine, 20 mg daily, experienced an increase in social affiliation compared with placebo-treated subjects, and higher plasma selective serotonin re-uptake inhibitor (SSRI) levels were correlated with increased affiliative behavior (Figure 2). Furthermore, Tancer and associates\textsuperscript{14} showed that following a challenge with fenfluramine, patients with social anxiety disorder exhibited significantly elevated cortisol levels compared with those of normal volunteers.

Dopamine dysregulation also is suspected in patients with generalized social anxiety disorder.\textsuperscript{15} Tiihonen and colleagues\textsuperscript{16} evaluated the density of dopamine reuptake sites in patients with social anxiety disorder. Patients with social anxiety disorder exhibited lower striatal dopamine reuptake site densities compared with healthy subjects. More recently, Schneier and associates (F. R. Schneier, M.D.; M.R.L.; A. Abi-Dargham, M.D.; et al., unpublished data, 1999) have found decreased striatal dopamine D\textsubscript{2} binding in patients with generalized social anxiety disorder compared with normal controls.

**TREATMENT**

Education and social support are important therapeutic components for patients with social anxiety disorder because these individuals are often isolated and have difficulty communicating with others. Many patients with social anxiety disorder feel that they alone have the condition. Appropriate education will help patients understand the illness, and social support may help patients cope with their symptoms and treatment.

Severity of illness, disease progression, and response to therapy may be monitored by a variety of clinical scales. The clinician-administered Liebowitz Social Anxiety Scale (LSAS: Appendix 3) is a 24-question scale that may be used to assess a patient’s fear and avoidance of social or performance situations.\textsuperscript{17} Other useful measures may include the Clinical Global Impressions scale,\textsuperscript{18} the Sheehan Disability Scale (Appendix 4), and the Brief Social Phobia Scale.\textsuperscript{19}

With regard to treatment, both pharmacologic (Table 2) and cognitive-behavioral approaches are effective, and the 2 modalities appear to have complementary strengths. The standard monoamine oxidase inhibitors (MAOIs) have well-demonstrated efficacy, and several controlled trials have shown marked acute benefits, even in highly dis-
Clinical Global Impressions—patients taking paroxetine (55%) were considered therapeutically effective, compared with 24% of placebo responders based on Clinical Global Impressions—patients with generalized social anxiety disorder. More than half of those treated with atenolol and placebo, respectively. Patients with generalized social anxiety disorder experienced the greatest response to phenelzine as compared with placebo. However, results with the reversible inhibitors of monoamine oxidase A have been more variable. In an 8-week study evaluating the efficacy of moclobemide compared with placebo in patients with social anxiety disorder, there were no significant differences in number of responders between treatment groups. Although the reversible inhibitors of monoamine oxidase A have fewer dietary restrictions compared with the MAOIs, these agents may not be promising in the treatment of social anxiety disorder. The high-potency benzodiazepine clonazepam also was effective in one trial and may be useful for treatment of acute symptoms. However, the incidence of relapse is high when benzodiazepines are discontinued.

The tricyclic antidepressants do not appear to be effective for the treatment of social anxiety disorder. More recently, the SSRIs, including paroxetine, fluvoxamine, sertraline, and fluoxetine, have shown substantial acute efficacy in clinical trials and are emerging as a first-line treatment for social anxiety disorder. The SSRIs are easily administered once daily and have a favorable adverse effect profile. Paroxetine is the most well studied SSRI to date in social anxiety disorder. In a double-blind, placebo-controlled study, the efficacy of paroxetine compared with placebo was evaluated in 187 patients with generalized social anxiety disorder. More than half of patients taking paroxetine (55%) were considered therapeutic responders based on Clinical Global Impressions—Global Improvement rating compared with 24% of patients treated with placebo (p < .001). In addition, patients treated with paroxetine had 39.1% reduction on the LSAS total score compared with 17.4% in the placebo group (Figure 3). These findings suggest that the SSRIs should be considered first-line therapy for patients with social anxiety disorder.

A limitation of all medications studied to date is the substantial rate of relapse observed even after prolonged treatment. Cognitive-behavioral therapy (CBT) is efficacious for acute therapy, although somewhat less so than the MAOI phenelzine. However, there appears to be a lower incidence of relapse following discontinuation of CBT. This provides a potent rationale for assessing the acute and long-term effects of combined CBT and pharmacotherapy.

### SUMMARY

Social anxiety disorder is a debilitating illness and should be regarded as a chronic disorder if left untreated. Furthermore, patients with social anxiety disorder often develop comorbid conditions and may suffer from substantial social and occupational dysfunction. Although the underlying pathophysiology of social anxiety disorder remains to be determined, there is evidence that central nervous system serotonergic and dopaminergic dysregulation may be involved, especially in the more disabling generalized subtype. Because patients with social anxiety disorder can be highly impaired functionally, aggressive diagnosis and treatment of the disorder are critical. Following appropriate diagnosis, the SSRIs may be considered initial therapy. The MAOIs also are effective and may be useful for treatment-refractory patients. Other agents, such as benzodiazepines or β-blockers, can be used on an as-needed or acute basis. In addition, psychosocial techniques can complement the effects of pharmacotherapy and may prevent relapse when medications are discontinued. Appropriate management of patients with social anxiety disorder will significantly improve quality of life and minimize psychosocial morbidity.

**Drug names:** atenolol (Tenormin and others), clonazepam (Klonopin and others), fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), phenelzine (Nardil), sertraline (Zoloft).

### REFERENCES

morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:
282–288
54(12, suppl):5–9
12. Levin AP, Saud J, Strautman T, et al. Responses of “generalized” and “discrete” social phobics during public speaking. J Anxiety Disord 1993;7:
207–221
22:89–90
17. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:
141–173
938–945
49:290–300
1992;161:353–360
152:1368–1371